Immunovant, Inc.

Health Sciences Acquisitions Corporation 2, which traded on Nasdaq under the ticker HSAQ, was a healthcare-focused blank-check company sponsored by OrbiMed Advisors that priced its IPO in 2018. The SPAC targeted biopharmaceutical and clinical-stage immunology opportunities. On December 20, 2019, Immunovant, Inc. filed an 8-K with the SEC under accession number 0001193125-19-321147, a current report associated with the closing of the companies' business combination. The combined entity, focused on FcRn inhibitor therapies for autoimmune diseases, subsequently traded on Nasdaq as IMVT. Sign up on SpacDesk for complete filing data, sponsor profiles, and deal analytics on this transaction and every active SPAC in the market.